SecSonar.com

Kiniksa Pharmaceuticals, Ltd. (KNSA)

Kiniksa Pharmaceuticals, Ltd. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Biotechnology company based in BM with a market capitalization of $3.7B. Revenue grew 60.1% year-over-year and the company generated $25.4M in free cash flow. This page tracks KNSA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

BM · 315 employees · IPO May 25, 2018

Valuation

Valuation & price

$52.86 · as of May 26, 2026 · -11.1% vs 52w high

70.8

P/E ratio

Latest-FY diluted EPS

6.43

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$59.20$42.77$26.33Jul 25Dec 25Jun 26Jul 7, 25$27.95Jul 9, 25$28.80Jul 11, 25$28.09Jul 15, 25$28.09Jul 17, 25$28.84Jul 21, 25$28.42Jul 23, 25$27.12Jul 25, 25$26.33Jul 29, 25$30.37Jul 31, 25$30.26Aug 4, 25$32.95Aug 6, 25$32.72Aug 8, 25$32.15Aug 12, 25$32.78Aug 14, 25$33.28Aug 18, 25$33.72Aug 20, 25$33.21Aug 22, 25$33.75Aug 26, 25$33.57Aug 28, 25$33.50Sep 3, 25$35.48Sep 5, 25$35.71Sep 9, 25$36.86Sep 11, 25$37.01Sep 15, 25$36.56Sep 17, 25$35.43Sep 19, 25$35.42Sep 23, 25$36.33Sep 25, 25$35.51Sep 29, 25$38.77Oct 1, 25$38.64Oct 3, 25$38.49Oct 7, 25$38.12Oct 9, 25$38.11Oct 13, 25$37.03Oct 15, 25$38.86Oct 17, 25$38.64Oct 21, 25$38.85Oct 23, 25$38.77Oct 27, 25$40.60Oct 30, 25$37.29Nov 3, 25$37.47Nov 5, 25$39.14Nov 7, 25$38.37Nov 11, 25$40.57Nov 13, 25$40.29Nov 17, 25$41.40Nov 19, 25$42.16Nov 21, 25$41.58Nov 25, 25$42.71Nov 28, 25$42.52Dec 2, 25$40.07Dec 4, 25$40.99Dec 8, 25$41.55Dec 10, 25$40.55Dec 12, 25$41.59Dec 16, 25$41.37Dec 18, 25$42.00Dec 22, 25$43.52Dec 24, 25$42.49Dec 29, 25$41.00Jan 2, 26$42.01Jan 6, 26$42.68Jan 8, 26$41.73Jan 12, 26$41.12Jan 14, 26$39.56Jan 16, 26$39.41Jan 21, 26$41.83Jan 23, 26$42.20Jan 27, 26$44.64Jan 29, 26$43.96Feb 2, 26$44.67Feb 4, 26$43.52Feb 6, 26$43.09Feb 10, 26$44.71Feb 12, 26$44.71Feb 17, 26$45.38Feb 19, 26$47.17Feb 23, 26$47.39Feb 25, 26$42.76Mar 2, 26$46.00Mar 4, 26$47.27Mar 6, 26$46.16Mar 10, 26$47.02Mar 12, 26$46.07Mar 16, 26$46.50Mar 18, 26$45.15Mar 20, 26$46.08Mar 24, 26$44.94Mar 26, 26$46.78Mar 30, 26$45.70Apr 1, 26$48.13Apr 6, 26$49.55Apr 8, 26$47.03Apr 10, 26$47.08Apr 14, 26$46.92Apr 16, 26$45.32Apr 20, 26$42.46Apr 22, 26$43.04Apr 24, 26$42.79Apr 28, 26$53.85May 1, 26$55.27May 5, 26$56.74May 7, 26$56.93May 11, 26$58.37May 13, 26$59.12May 15, 26$56.51May 19, 26$53.34May 21, 26$53.65May 26, 26$52.86May 28, 26$50.84Jun 1, 26$48.43Jun 3, 26$47.85Jun 5, 26$48.42Jun 9, 26$48.70Jun 11, 26$51.58Jun 15, 26$52.34Jun 17, 26$54.21Jun 22, 26$57.13Jun 26, 26$59.20
$26.3352-week range$59.49
Loading valuation history…

Fundamentals

Key fundamentals

$3.7B

Market cap

60.1%

Revenue growth (YoY)

54.6%

Gross margin

$25.4M

Free cash flow (USD)

-$404.6M

Net debt

Net cash position

3.9%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$0.00FY 2019$0.00FY 2020$0.00FY 2021$38.5MFY 2022$220.2MFY 2023$270.3MFY 2024$423.2MFY 2025$677.6M
$0$677.6M

Free cash flow by year

2016 → 2025

FY 2016$-21.9MFY 2017$-50.3MFY 2018$-86.3MFY 2019$-161.6MFY 2020$-136.8MFY 2021$-146.7MFY 2022$5.7MFY 2023$13.2MFY 2024$25.4MFY 2025$25.4M
-$21.9M$25.4M

Gross margin by year

2021 → 2025

FY 202176.4%FY 202289.6%FY 202379.1%FY 202485.6%FY 202554.6%
76.4%54.6%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

9

Insider sells · 90 days

Earnings

Last report: 10-Q filed Apr 28, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsMay 29, 2026Filing
  • 8-K eventWaiver of Conversion RightsMay 26, 2026Filing
  • Insider sellInsider Sell $3.1M · 10b5-1 PlanPaolini John F. · CHIEF MEDICAL OFFICER · $3.1MMay 5, 2026Filing
  • Insider sellInsider Sell $2.6M · 10b5-1 PlanPatel Sanj K · Director, CHAIRMAN & CEO · $2.6MMay 1, 2026Filing
  • 8-K eventChief Strategy Officer ResignationMay 1, 2026Filing
  • Insider sellInsider Sell $26.4M · 10b5-1 PlanPatel Sanj K · Director, CHAIRMAN & CEO · $26.4MApr 30, 2026Filing
  • Insider sellInsider Sell $656K · 10b5-1 PlanQuart Barry D · Director · $656.3KApr 29, 2026Filing
  • 8-K eventEarnings ReleaseApr 28, 2026Filing
  • Quarterly report10-Q FiledApr 28, 2026Filing
  • Insider sellInsider Sell $80K · 10b5-1 PlanMoat Ross · CHIEF OPERATING OFFICER · $79.5KApr 13, 2026Filing

Questions

Frequently asked questions

What is Kiniksa Pharmaceuticals, Ltd.'s market cap?

Kiniksa Pharmaceuticals, Ltd. (KNSA) has a market capitalization of $3.7B.

What is KNSA's P/E ratio?

KNSA trades at a price-to-earnings ratio of 70.8, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is KNSA's price-to-book (P/B) ratio?

KNSA trades at 6.43 times book value per share.

Are insiders buying KNSA stock?

SEC Form 4 filings show no open-market insider buys at Kiniksa Pharmaceuticals, Ltd. in the last 90 days (9 sells).

Same arena

Related companies in Biotechnology

ACAD

ACADIA Pharmaceuticals Inc.

$3.7B

CRNX

Crinetics Pharmaceuticals, Inc.

$3.7B

VCYT

Veracyte, Inc.

$3.8B

DNTH

Dianthus Therapeutics, Inc.

$3.8B

CPRX

Catalyst Pharmaceuticals, Inc.

$3.8B

BEAM

Beam Therapeutics Inc.

$3.4B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.